References
- Martinez MN . Welcome to the animal pharmaceuticals special focus.Future Med. Chem.3(7), 845–846 (2011).
- Cardiff RD , WardJM, BartholdSW. ‘One medicine – one pathology‘: are veterinary and human pathology prepared?.Lab. Invest.88(1), 18–26 (2008).
- Paoloni M , DavisS, LanaSet al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10, 625 (2009).
- Breen M . Update on genomics in veterinary oncology.Top Companion Anim. Med.24(3), 113–121 (2009).
- Vail DM , MacEwenEG. Spontaneously occurring tumors of companion animals as models for human cancer.Cancer Invest.18(8), 781–792 (2000).
- Khanna C , VailDM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers.Curr. Cancer Drug Targets3(4), 265–273 (2003).
- Pinho SS , CarvalhoS, CabralJ, ReisCA, GärtnerF. Canine tumors: a spontaneous animal model of human carcinogenesis.Transl. Res.159(3), 165–172 (2012).
- Mueller F , FuchsB, Kaser-HotzB. Comparative biology of human and canine osteosarcoma.Anticancer Res.27(1A), 155–164 (2007).
- Rankin KS , StarkeyM, LunecJ, GerrandCH, MurphyS, BiswasS. Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.Pediatr. Blood Cancer58(3), 327–333 (2012).
- Brown DC , BostonR, CoyneJC, FarrarJT. A novel approach to the use of animals in studies of pain: validation of the canine brief pain inventory in canine bone cancer.Pain Med.10(1), 133–142 (2009).
- Queiroga FL , RaposoT, CarvalhoMI, PradaJ, PiresI. Canine mammary tumours as a model to study human breast cancer: most recent findings.In Vivo25(3), 455–465 (2011).
- Klopfleisch R , LenzeD, HummelM, GruberAD. The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas.Vet. J.190(2), 236–243 (2011).
- Vail DM , MichelsGM, KhannaCet al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) – a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet. Comp. Oncol. 8(1), 28–37 (2010).
- Leblanc AK , MillerAN, GalyonGDet al. Preliminary evaluation of serial 18FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer. Vet. Radiol. Ultrasound 53(3), 348–357 (2012).
- Croom KF , PerryCM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.Drugs63(5), 513–522; discussion 523–524 (2003).
- Postow MA , CarvajalRD. Therapeutic Implications of KIT in Melanoma.Cancer J.18(2), 137–141 (2012).
- London CA . Tyrosine kinase inhibitors in veterinary medicine.Top. Companion Anim. Med.24(3), 106–112 (2009).
- Misdorp W . Mast cells and canine mast cell tumours. A review.Vet. Q.26(4), 156–169 (2004).
- Metcalfe DD . Regulation of normal and neoplastic human mast cell development in mastocytosis.Trans. Am. Clin. Climatol. Assoc.116, 185–203; discussion 203–204 (2005).
- Paoloni MC , MazckoC, FoxEet al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS ONE 5(6), e11013 (2010).
- London CA , BearMD, McCleeseJet al. Phase I evaluation of STA-1474, a prodrug of the novel Hsp90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS ONE 6(11), e27018 (2011).